Foy Karlissa, Juethner Salomé N
Community Research Initiative of New England, Boston, USA.
J Assoc Nurses AIDS Care. 2004 Nov-Dec;15(6):65-71. doi: 10.1177/1055329003256414.
Enfuvirtide is a fusion inhibitor used for the treatment of HIV infection. It is an injectable drug, with the patient being responsible for reconstitution as well as injection. The authors present the results of Phase III trials with enfuvirtide. A summary of efficacy, tolerability, pharmacokinetics, resistance, and adverse events from the Phase III trials with enfuvirtide is presented. Enfuvirtide is well tolerated, and no limiting pharmacokinetic interactions have been published thus far. A review of patient perception of self-injection is also summarized. The data reviewed demonstrate that most patients find self-injection easy and do not find that it interferes with activities of daily living. Data on injection site reactions (ISRs), one of the most common adverse events of enfuvirtide, is highlighted, as is nursing management of ISRs. Finally, the authors discuss research that could help further understanding of enfuvirtide and examine some barriers clinicians may face when prescribing this medication.
恩夫韦肽是一种用于治疗HIV感染的融合抑制剂。它是一种注射用药物，由患者负责复溶及注射。作者展示了恩夫韦肽III期试验的结果。文中呈现了恩夫韦肽III期试验的疗效、耐受性、药代动力学、耐药性及不良事件的总结。恩夫韦肽耐受性良好且迄今为止尚未发表有具有限制作用的药代动力学相互作用。文中还总结了对患者自我注射感受的回顾。所回顾的数据表明大多数患者觉得自我注射很容易，且并未发现其干扰日常生活活动。文中重点介绍了注射部位反应（ISR）的数据，这是恩夫韦肽最常见的不良事件之一，同时还介绍了ISR的护理管理。最后，作者讨论了有助于进一步了解恩夫韦肽的研究，并探讨了临床医生在开具此药物处方时可能面临的一些障碍。
